Thus, synergism of TNF/TNFR1 deficiency and anti-PD-1 is likely not restricted to melanoma but applies to other cancers, such as lung carcinoma, which can benefit from anti-PD-1 according to phase 2 and phase 3 clinical trials25,26. This evidence concerns the gene PDCD1 and lung carcinoma.